MID AND SOUTH ESSEX MEDICINES OPTIMISATION COMMITTEE (MSEMOC)

IXEKIZUMAB FOR TREATING AXIAL SPONDYLOARTHRITIS, NICE TA718, JULY 2021

RED – RECOMMENDED FOR RESTRICTED USE in Secondary Care

Name: generic (trade)	What it is	Licensed indications	Decision status	NICE guidance
IXEKIZUMAB (Taltz®)	**Ixekizumab is an IgG4 monoclonal antibody that binds with high affinity (< 3 pM) and specificity to interleukin 17A (both IL-17A and IL-17A/F)**	**Treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy; treatment of adult patients with active non-radiographic axial spondyloarthritis who have responded inadequately to nonsteroidal anti-inflammatory drugs**	**Final**	**NICE TA718 – recommended**

MSEMOC recommendation:

Ixekizumab is recommended as a treatment option for axial spondyloarthritis in accordance with NICE technology appraisal recommendations.

NICE TA718 recommendation:

1.1 Ixekizumab is recommended as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy, or active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs), in adults. It is recommended only if:

- tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough, and
- the company provides ixekizumab according to the commercial arrangement.

1.2 Assess response to ixekizumab after 16 to 20 weeks of treatment. Continue treatment only if there is clear evidence of response, defined as:

- a reduction in the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score to 50% of the pre-treatment value or by 2 or more units and
- a reduction in the spinal pain visual analogue scale (VAS) by 2 cm or more.

1.3 Take into account any communication difficulties, or physical, psychological, sensory or learning disabilities that could affect responses to the BASDAI and spinal pain VAS questionnaires and make any appropriate adjustments.

1.4 These recommendations are not intended to affect treatment with ixekizumab that was started in the NHS before this guidance was published. People having treatment outside these recommendations may continue without change to the funding arrangements in place for them before this guidance was published, until they and their NHS clinician consider it appropriate to stop.

For further information refer to the Summary of Product Characteristics for ixekizumab.

Providers commissioned to provide services on behalf of Mid and South Essex CCGs are reminded that they are required to follow the local joint formulary and prescribing guidance, as detailed in the medicines management service specification of their contract.

References	NICE TA718: Ixekizumab for treating axial spondyloarthritis: https://www.nice.org.uk/guidance/ta718
Acknowledgements	Mid and South Essex CCGs Medicines Management Teams
Version	1.0
Author	HCPMSEMOC working group
Approved by	MSEMOC
Date Approved	October 2021
Review Date	October 2026 or sooner if subject to any new updates nationally